| 2018-08-09 05:48:48|
PRGO 05:48 08/09 08/09/18
Perrigo sees FY18 adj. EPS $4.75-$4.95, consensus $5.20
Primarily due to revised expectations for the RX segment and unfavorable foreign currency translation of $65 million, the company now expects calendar year 2018 net sales to be in the range of $4.8B-$4.9B, consensus $5.01B.